Biggest News Aggregation in the World
📰 Representing Approximately News

Representing Approximately News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Representing Approximately. Real-time updates on events, politics, business and more.

Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA

Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Company's Biosimilars Business, and the Estimated Retained Value are in Line with the Company's Previously Communicated RangeStrategic Decision Made to Retain Rights...
United States Andhra Pradesh Poitou Charentes Insud Pharma Scotta Smith Percent Of The Company Global Workforce Being

Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original Total Target of a Multiple Above 12x on 2022 Estimated Adjusted EBITDA

Total Gross Proceeds From All Divestitures, Including the 2022 Divestiture of the Companys Biosimilars Business, and the Estimated Retained Value are in Line with the Companys Previously...
Andhra Pradesh United States Poitou Charentes Insud Pharma Scotta Smith Company Previously Communicated

ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System

Royalty-Bearing License Agreement Covers the Countries in the Indian Subcontinent, Representing Approximately 20% to 25% of the World’s PopulationIRVINE, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of an exclusive, royalty-bearing license agreement with Biorad Medysis, Pvt. Ltd. (Biorad) to manufacture, commercialize and distribute the Obalon&#...
Sri Lanka United States Paulf Hickey Michael Miller Biorad Medysis Thomas Stankovich
Source: yahoo.com

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

17.01.2023 - Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 ... Seite 1
Adam Grossman Biologics Inc Full Year Representing Approximately Year Over Growth During Second Half

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science